JULY 13, 2016
As published in the San Antonio Business Journal
By W. Scott Bailey
One of San Antonio’s more promising bioscience companies, bioAffinity Technologies Inc., has locked up a key deal, renewing its collaborative agreement with the University of Texas Health Science Center at San Antonio.
The extension will allow the two organizations to continue working together on the research and development of novel cancer diagnostic and therapeutic agents using bioAffinity’s porphyrin-based technology platform. This is the fourth year bioAffinity and the Health Science Center have entered into such an agreement.
Alexander Pertsemlidis, Ph.D., who is affiliated with the Greehey Children’s Cancer Research Institute, will lead the Health Science Center’s research team. Pertsemlidis will work with a bioAffinity science team led by Dr. Vivienne Rebel, who previously had her own research group at the Health Science Center.
Maria Zannes, president and CEO of bioAffinity Technologies, said the collaborative agreement will allow more world-class researchers and scientists to work in tandem toward the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics addressing multiple cancers.
The San Antonio company’s initial product is the CyPath Lung diagnostic. Its new subsidiary, OncoSelect Therapeutics Inc., plans to build on bioAffinity’s porphyrin-based diagnostics to create targeted therapeutics to deliver chemotherapy drugs directly into cancer cells.
